Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Chief Medical Officer | April 02, 2025 | April 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date April 02, 2025 · Filed April 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2035-04-02 | Direct | 215,000 |
Reported balance
After 2025-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-02 · Grant · Acquired 215,000 · Balance 215,000 F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2025 Filed Apr 4, 2025 20:09 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000905148-25-001092 · form4.xml · derivative · entry 1 Ahmad Qasim Iftikhar · CIK 0001985801 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2035-04-02 F1 · derivative.exercise_date: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:50 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 31,350 | $0.85 | $26,553.45 |
DisclosureSEC source: 0000905148-24-003414 · form4.xml · nonDerivative · entry 1 Ahmad Qasim Iftikhar · CIK 0001985801 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,350 Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 20:18 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000905148-24-000966 · form4.xml · derivative · entry 1 Ahmad Qasim Iftikhar · CIK 0001985801 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2034-03-15 F1 · derivative.exercise_date: One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:20 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 288,153 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001140361-23-035207 · form4.xml · derivative · entry 1 Ahmad Qasim Iftikhar · CIK 0001985801 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,153 Underlying: Common Stock · 288,153 shares Expires 2033-07-17 F1 · derivative.exercise_date: One-fourth of these options vest on July 17, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the Issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.